The company plans to use proceeds to advance its lead AR-V7 test with Genomic Health, accelerate other assays in its pipeline, and enhance its technology.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
At the AACR annual meeting earlier this month, attendees discussed challenges in demonstrating analytical and clinical validity appropriately for liquid biopsy tests.
At the AACR annual meeting last week researchers presented new data on a range of technologies, discussed novel platforms, compared existing tools, and explored new clinical uses.
The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.
With new research and commercial test launches, clincians anticipate exciting new tools but judging quality and utility has become challenging.
The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
The company said it accessioned 1,175 total samples during the quarter, up from 663 total samples in Q4 2015.
Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.
The combination test will allow clinicians to analyze breast cancer patients for germline hereditary cancer markers at the same time as they search their blood for driver mutations.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.